share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(8.3%),Stockton Limited(8.3%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(8.3%),Stockton Limited(8.3%), etc.

SC 13G/A：超過5%持股股東披露文件(修正)-Nirland Limited(8.3%),Stockton Limited(8.3%)等
美股SEC公告 ·  10/07 19:38

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed an amendment to Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant shareholding by a group of related entities. The filing, dated October 4, 2024, reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey, collectively hold 8,092,000 shares of Conduit Pharmaceuticals' common stock, representing 8.3% of the company. This stake includes both direct ownership and shares issuable upon the exercise of warrants. The entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to their investment in Conduit Pharmaceuticals. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed an amendment to Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant shareholding by a group of related entities. The filing, dated October 4, 2024, reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey, collectively hold 8,092,000 shares of Conduit Pharmaceuticals' common stock, representing 8.3% of the company. This stake includes both direct ownership and shares issuable upon the exercise of warrants. The entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to their investment in Conduit Pharmaceuticals. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Conduit Pharmaceuticals Inc.，之前被稱爲Murphy Canyon Acquisition corp，已向美國證券交易委員會（SEC）提交了13G表格的修正，表明一組相關實體持有重要的參股金融。文件日期爲2024年10月4日，顯示Nirland Limited，Stockton Limited，The Rowland Master Trust和Dovet Limited，所有在格恩西註冊，共持有Conduit Pharmaceuticals普通股的8,092,000股，佔公司的8.3%。這一持有包括直接所有權和根據認股證行使而增發的股份。這些實體已簽署了聯合申報協議，表明他們在Conduit Pharmaceuticals投資方面採取協調的方式。該文件強調這些股份不是爲了改變或影響發行人的控制而獲得的。
Conduit Pharmaceuticals Inc.，之前被稱爲Murphy Canyon Acquisition corp，已向美國證券交易委員會（SEC）提交了13G表格的修正，表明一組相關實體持有重要的參股金融。文件日期爲2024年10月4日，顯示Nirland Limited，Stockton Limited，The Rowland Master Trust和Dovet Limited，所有在格恩西註冊，共持有Conduit Pharmaceuticals普通股的8,092,000股，佔公司的8.3%。這一持有包括直接所有權和根據認股證行使而增發的股份。這些實體已簽署了聯合申報協議，表明他們在Conduit Pharmaceuticals投資方面採取協調的方式。該文件強調這些股份不是爲了改變或影響發行人的控制而獲得的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間